NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH

Phase 2 Completed 30 enrolled Population Health Research Institute

RandomizedParallel-groupSingle-blindTreatment

Summary

To determine the feasibility of a controlled trial examining the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) compared with ASA for stroke prevention in patients with a high-risk of atrial fibrillation and previous intracerebral hemorrhage.

Timeline

Start: 2017-04-26
Primary completion: 2019-10-31
Completion: 2020-02-18

Publications

Cochrane A, Chen C, Stephen J, Ronning OM, Anderson CS, Hankey GJ, Al-Shahi Salman R. Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD012144. doi: 10.1002/14651858.CD012144.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apixaban	Small molecule	—	Oral
Comparator	Aspirin	Small molecule	81 mg	—
Subject	Dabigatran	Unknown	—	Oral
Subject	Edoxaban	Small molecule	—	Oral
Subject	Rivaroxaban	Other / unclassified	—	Oral

NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH

Summary

Timeline

Publications

Drugs

Indications